BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20806582)

  • 1. Why pick on propoxyphene? The evidence demands it.
    Hutchison LC
    J Ark Med Soc; 2010 Aug; 107(2):36-7. PubMed ID: 20806582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propoxyphene and pain management in the elderly.
    Mort JR; Schroeder SD
    S D Med; 2009 Nov; 62(11):433-5. PubMed ID: 20128173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity.
    Barkin RL; Barkin SJ; Barkin DS
    Am J Ther; 2006; 13(6):534-42. PubMed ID: 17122535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food and Drug Administration recommends against the continued use of propoxyphene.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2011; 25(1):80-2. PubMed ID: 21426228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dextropropoxyphene: withdrawal from the US market requested: harmful drug.
    Prescrire Int; 2009 Aug; 18(102):166-7. PubMed ID: 19746529
    [No Abstract]   [Full Text] [Related]  

  • 6. Pain treatment agreements.
    Rowe W
    Am J Bioeth; 2010 Nov; 10(11):3-4. PubMed ID: 21104544
    [No Abstract]   [Full Text] [Related]  

  • 7. Dextropropoxyphene: welcome withdrawal from a French hospital's formulary.
    Prescrire Int; 2008 Jun; 17(95):112. PubMed ID: 18629970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Close vote by FDA advisers favors propoxyphene withdrawal.
    Traynor K
    Am J Health Syst Pharm; 2009 Mar; 66(6):518-20. PubMed ID: 19265176
    [No Abstract]   [Full Text] [Related]  

  • 9. It is time to remove propoxyphene from clinical practice.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2009; 23(2):104-5. PubMed ID: 19492210
    [No Abstract]   [Full Text] [Related]  

  • 10. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties.
    Arnold RM; Han PK; Seltzer D
    Am J Med; 2006 Apr; 119(4):292-6. PubMed ID: 16564767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propoxyphene use and risk for hip fractures in older adults.
    Kamal-Bahl SJ; Stuart BC; Beers MH
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):219-26. PubMed ID: 17062322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consumer group urges Food and Drug Administration to ban drug Darvon.
    Willens JS
    Pain Manag Nurs; 2006 Jun; 7(2):43. PubMed ID: 16730316
    [No Abstract]   [Full Text] [Related]  

  • 13. D-propoxyphene and dipyrone co-administration produces greater antinociception and fewer adverse effects than single treatments in rats.
    Silva-Moreno A; López-Muñoz FJ; Cruz SL
    Eur J Pharmacol; 2009 Apr; 607(1-3):84-90. PubMed ID: 19232342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems with propoxyphene.
    Perin ML
    Am J Nurs; 2000 Jun; 100(6):22. PubMed ID: 10892320
    [No Abstract]   [Full Text] [Related]  

  • 15. Dextropropoxyphene: withdrawn in the EU. Withdrawn from pharmacies in France.
    Prescrire Int; 2009 Aug; 18(102):166. PubMed ID: 19746528
    [No Abstract]   [Full Text] [Related]  

  • 16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA to tighten labeling on long acting opioids.
    McCarthy M
    BMJ; 2013 Sep; 347():f5581. PubMed ID: 24030791
    [No Abstract]   [Full Text] [Related]  

  • 18. The Food and Drug Administration opioid Risk Evaluation and Mitigation Strategy.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2009; 23(3):219-21. PubMed ID: 19670017
    [No Abstract]   [Full Text] [Related]  

  • 19. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
    Sloan PA
    J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
    [No Abstract]   [Full Text] [Related]  

  • 20. We can make opioids safer.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):112-3. PubMed ID: 23688516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.